Outcome measurement in clinical genetics services: a systematic review of validated measures.

OBJECTIVE: This systematic review aimed to inform researchers and policymakers about what validated outcome measures are available to evaluate clinical genetics services (CGS) and the need for new measures. METHODS: Validated outcome measures used to evaluate CGS were identified from a systematic literature review. Subjective outcome measures were assumed to have been validated only if some form of psychometric assessment was reported. RESULTS: A total of 1688 titles and abstracts were identified, and 61 articles met the inclusion criteria for the final review, which covered 67 validated outcome measures. There were 37 nongenetics-specific and 30 genetics-specific measures identified. No single validated outcome measure encompassed all potential patient benefits from using a CGS. A variety of different domains were identified, including anxiety and depression, coping, decision-making, distress, family environment, health status, knowledge, mood, perception of risk, perceived personal control, psychological impact, quality of life, satisfaction and expectations, self-esteem, spiritual well-being, and worry. Some important aspects of patient benefit from CGS are not covered by existing outcome measures. CONCLUSIONS: New research is necessary to develop the array of outcome measures required to quantify the benefits CGS offer patients living with the effects of genetic conditions. These need to be suitable for use in prospective evaluation studies to provide robust evidence for decision-makers to inform service development and commissioning. This includes prioritization of the existing validated outcome measures in terms of their usefulness and relevance to the measurement and valuation of patient benefits from a CGS. [References: 83]

Aim

This systematic review aimed to inform researchers and policymakers about what validated outcome measures are available to evaluate CGS and the need for new measures. Specific objectives were to identify existing validated outcome measures used in evaluations of CGS and the key domains captured by these measures.

Contributors

Payne, K. Nicholls, S. McAllister, M. Macleod, R. Donnai, D. Davies, L. M.

Publication

Journal: Value in Health
Volume: 3
Issue:
Pages: 497 - 508
Year: 2008
DOI: 10.1111/j.1524-4733.2007.00259.x

Further Study Information

Current Stage: Not Applicable
Date: February 2006
Funding source(s): Nowgen, The NorthWest Genetics Knowledge Park, is funded by a grant from the Department of Health and the Department of Trade and Industry. Funding is also acknowledged from Central Manchester and Manchester Children’s Hospitals NHS Trust and the Universities of Manchester, Liverpool, and Lancaster.


Health Area

Disease Category: Genetic disorders

Disease Name:

Target Population

Age Range: 0 - 100

Sex: Either

Nature of Intervention: Not specified

Stakeholders Involved

- None

Study Type

- Systematic review of outcome measures/measurement instruments

Method(s)

- Systematic review

Validated outcome measures used to evaluate CGS were identified from a systematic literature review.

Electronic searches of MEDLINE (Ovid, 1966 to date), Embase (Ovid, 1980 to date), PsychInfo (Ovid, 1806 to date), HAPI (Ovid, 1985 to date) and the Cochrane Library (1900–2005), which includes NHS Economic Evaluation Database and Database of Abstracts of Reviews of Effectiveness, were conducted (February 2006).